Evidence map›Paper›PMID 32399283›Full record

ReviewJournal of gastrointestinal oncology2020

Application of photodynamic therapy for liver malignancies.

Heng Zou, Fusheng Wang, Jiang-Jiao Zhou, Xi Liu, Qing He, Cong Wang, Yan-Wen Zheng, Yu Wen, Li Xiong

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of gastrointestinal oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Optimal Use of 2',7'-Dichlorofluorescein Diacetate in Cultured Hepatocytes.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Silica-Based Nanoframeworks Involved Hepatocellular Carcinoma Theranostic.Frontiers in bioengineering and biotechnology · 2021
    Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Heng ZouDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
Fusheng WangDepartment of General Surgery, Fuyang People's Hospital, Fuyang 236000, China.
Jiang-Jiao ZhouDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
Xi LiuDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
Qing HeDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
Cong WangDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
Yan-Wen ZhengDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
Yu WenDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
Li XiongDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
Central South University · CNSecond Xiangya Hospital of Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver malignancies include primary and metastatic tumors. Limited progress has been achieved in improving the survival rate of patients with advanced stage liver cancer and who are unsuitable for surgery. Apart from surgery, chemoradiotherapy, trans-arterial chemoembolization and radiofrequency ablation, a novel therapeutic modality is needed for the clinical treatment of liver cancer. Photodynamic therapy (PDT) is a novel strategy for treating patients with advanced cancers; it uses a light-triggered cytotoxic photosensitizer and a laser light. PDT provides patients with a potential treatment approach with minimal invasion and low toxicity, that is, the whole course of treatment is painless, harmless, and repeatable. Therefore, PDT has been considered an effective palliative treatment for advanced liver cancers. To date, PDT has been used to treat hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma and liver metastases. Clinical outcomes reveal that PDT can be considered a promising treatment modality for all liver cancers to improve the quality and quantity of life of patients. Despite the advances achieved with this approach, several challenges still impede the application of PDT to liver malignancies. In this review, we focus on the recent advancements and discuss the future prospects of PDT in treating liver malignancies.

Indexed as

liver malignanciesnew modality for cancerPhotodynamic therapy (PDT)photosensitizer

Identifiers

PMID32399283
PMCPMC7212095
OpenAlexW3013607821

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.